Promoting schizophrenia research in Europe: the contribution of the European Group for Research in Schizophrenia
Author:
- 15 September 2023
- journal article
- letter
- Published by Wiley in World Psychiatry
- Vol. 22 (3) , 486-487
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)The Lancet Psychiatry, 2023
- Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participantsWorld Psychiatry, 2022
- European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter StudyFrontiers in Psychiatry, 2022
- A large European, multicenter, multinational validation study of the Brief Negative Symptom ScaleEuropean Neuropsychopharmacology, 2019
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialThe Lancet, 2008
- The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trialSchizophrenia Research, 2005